NCT03954652View on ClinicalTrials.gov

"Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - GENOME FIRST APPROACH"

NACompletedINTERVENTIONAL

Enrollment

1,350

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2022

Conditions

Rare DiseasesGenetic Predisposition

Interventions

GENETIC

WGS-Diagnostic

Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.

Trial Locations (1)

72076

University Hospital Tübingen, Tübingen

All Listed Sponsors

lead

University Hospital Tuebingen

OTHER

NCT03954652 - "Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - GENOME FIRST APPROACH" | Biotech Hunter | Biotech Hunter